Biote reports Q1 revenue $46.8M (+4.4%), net loss narrows to $5.8M; reaffirms 2024 guidance

biote Corp.

2024-Q1 EPS reported -$0.06 revenue$46,804,000

Revenue $46.8M (+4.4% YoY); procedure revenue $37.4M (+6.6%).
Net loss $(5.8)M vs $(21.4)M prior year; EPS $(0.06) vs $(0.39).
Adjusted EBITDA $14.2M (+8.0%); margin 30.2% (+100bps).
Gross margin 71.4% (+240bps) on improved mix.
BioteRx launch progressing; reaffirms FY2024 guidance with H2 acceleration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

biote Corp. reported first quarter ended March 31, 2024 results: revenue Revenue of $46.8 million, net income Net loss of $(5.8) million, EPS basic and diluted loss per share attributable to biote Corp. stockholders of $(0.06). Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: Revenue of $46.8 million
Net income: Net loss of $(5.8) million
EPS: basic and diluted loss per share attributable to biote Corp. stockholders of $(0.06)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) • Revenue of $46.8 million, up 4.4% • Procedure revenue of $37.4 million, up 6.6% • Gross profit margin of 71.4%, an approximately 240-basis point increase • Net loss of $(5.8) million, representing net

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

biote Corp. filing history →

Source: SEC EDGAR

accession 0001193125-24-133133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.